Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In Re: MYLAN N.V. SECURITIES LITIGATION
Case Number:
1:16-cv-07926
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Bernstein Liebhard
- Bernstein Litowitz
- Cohen Milstein
- Cozen O'Connor
- Cravath Swaine
- Kaplan Rice
- Pomerantz LLP
Companies
Government Agencies
Sectors & Industries:
-
April 06, 2020
Mylan Investors Get Cert. In EpiPen Securities Fraud Action
A New York federal judge granted certification Monday to a class of thousands of Mylan NV investors who say the pharmaceutical giant committed securities fraud by misleading them about how it was allegedly overcharging Medicaid for EpiPen purchases and engaging in other anti-competitive conduct.
-
March 29, 2019
Mylan Gets Some Parts Of Investors' EpiPen Suit Trimmed
After trimming some claims and statements, a New York federal judge said Friday that he would not dismiss all of the new claims in an amended investor suit against Mylan NV over allegedly anti-competitive behavior involving its EpiPen epinephrine auto-injector.
-
September 06, 2018
Mylan Investors Push Back At Bid To Toss EpiPen Claims
Investors in Mylan NV fired back at what they called a scattershot motion to dismiss their amended claims about alleged anti-competitive behavior involving the drugmaker's EpiPen epinephrine auto-injector, saying their latest allegations are "well-pleaded and damning."
-
August 07, 2018
Mylan Wants Investors' 'Copycat' EpiPen Claims Dismissed
Drugmaker Mylan NV on Monday urged a New York federal court to dismiss investors' amended allegations about alleged anti-competitive behavior involving its EpiPen epinephrine autoinjector, saying the bulk of the allegations were simply copied from other complaints.
-
March 29, 2018
Mylan Must Face Many Of Investors' EpiPen Fraud Claims
EpiPen maker Mylan NV must face a trimmed-down proposed securities fraud class action accusing it of misleading investors about how it was allegedly overcharging Medicaid for EpiPen purchases and engaging in other anti-competitive conduct, a New York federal judge ruled Wednesday.
-
August 11, 2017
Mylan Can't Duck Securities Fraud Suit, Investors Say
Investors in EpiPen maker Mylan NV have pushed back against the pharmaceutical company's bid to toss their securities fraud proposed class action, telling a New York federal court that Mylan hasn't even challenged two of the categories of misstatements alleged in their complaint.
-
May 31, 2017
EpiPen Maker Says Securities Fraud Allegations Don't Add Up
EpiPen maker Mylan NV asked a New York federal judge on Tuesday to throw out a shareholder suit that accuses it of securities fraud, saying the investors' references to other investigations and lawsuits that have hurt its stock price in recent years don't amount to proof of wrongdoing.
-
October 11, 2016
Mylan's EpiPen Rebate Errors Spark SEC Probe, Investor Suit
The damage Mylan is facing for underpaying Medicaid rebates by misclassifying the EpiPen as a generic drug hasn't ended with Friday's $465 million Justice Department settlement, as the U.S. Securities and Exchange Commission and investors have respectively launched an investigation and a potential class action in New York.